Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000–2009
OBJECTIVE: To assess the treatment outcomes of MDR-TB patients over a period of 10 years in The Netherlands.
DESIGN: Demographic, clinical and microbiological features of all patients with MDR-TB who started treatment in 2000–2009 in the Netherlands were analysed from national registry and patient records.
RESULTS: Characteristics of the 113 MDR-TB patients were as follows: male/female ratio 1.57, 96% foreign born, median age 29 years, 96 (85%) pulmonary TB, 56 (50%) smear-positive, 14 (12%) human immunodeficiency virus (HIV) co-infected. Of the 104 (92%) patients who started MDR-TB treatment, 86% had a successful outcome using a median of six active drugs; eight underwent pulmonary surgery. HIV negativity was associated with successful outcome (adjusted OR 2.1, 95%CI 1.1–3.8).
CONCLUSION: High success rates for MDR-TB treatment were achieved with close collaboration of all stakeholders, reaching the targets set for drug-susceptible TB. HIV remained an independent risk factor for unsuccessful treatment outcome.
Keywords: HIV; MDR-TB; drug susceptibility testing; outcome; public health; therapeutic drug monitoring
Document Type: Research Article
Affiliations: 1: Tuberculosis Center Beatrixoord, University Medical Center Groningen, Department of Pulmonary Medicine & Tuberculosis, University of Groningen, Haren, The Netherlands 2: KNCV Tuberculosis Foundation, The Hague, The Netherlands; Centre for Infectious Diseases, National Institute of Public Health and the Environment, Bilthoven, The Netherlands 3: Tuberculosis Center, University Center for Chronic Diseases Dekkerswald, Radboud Nijmegen University Medical Center, Nijmegen, The Netherlands 4: KNCV Tuberculosis Foundation, The Hague, The Netherlands; Academic Medical Center, Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands 5: Tuberculosis Reference Laboratory, Centre for Infectious Diseases, National Institute for Health and the Environment (RIVM), Bilthoven, The Netherlands; Departments of Medical Microbiology and Lung Disease, Radboud Nijmegen University Medical Center, Nijmegen, The Netherlands 6: Tuberculosis Center Beatrixoord, University Medical Center Groningen, Department of Pulmonary Medicine & Tuberculosis, University of Groningen, Haren, The Netherlands; University Medical Center Groningen, Department of Internal Medicine, Infectious Diseases, University of Groningen, The Netherlands
Publication date: 01 April 2015
The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.
The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content